Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of APG-115 plus toripalimab in advanced liposarcoma or other advanced solid tumors
CTR20210367Phase 2Active
- Sponsor
- Suzhou Yasheng Pharmaceutical
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alrizomadlin, toripalimab in Liposarcoma, Nonhematologic neoplasms, sponsored by Suzhou Yasheng Pharmaceutical. Started Jun 2021; status: active.
02
Drugs
alrizomadlintoripalimab
03
Conditions
LiposarcomaNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20210367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210367.